Modern Biopharmaceuticals, Design, Development and Optimization; Volume 3 : Production of Biopharmaceuticals

Knäblein, Jörg

ISBN 10: 352731184X / ISBN 13: 9783527311842

Published by Wiley, Germany, 2005

About this Item

352731184X. Volume 3; Pictorial board hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 635 pages, index, illustrated with charts, tables and diagrams. The biopharmaceutical market has come a long way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. The global market for biopharmaceuticals, has been growing at an impressive compound annual growth rate of 210. This segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade. Contents as new, clean, tight and bright.

Seller Inventory # 027194

Bibliographic Details

• Title: Modern Biopharmaceuticals, Design, Development and Optimization; Volume 3 : Production of Biopharmaceuticals
• Publisher: Wiley, Germany
• Publication Date: 2005
• Language: English
• ISBN 10: 352731184X
• ISBN 13: 9783527311842
• Binding: Hardcover
• Condition: Fine
• Book Type: Book
• Seller catalogs:
  • Pharmaceutical Industry

About this title

Synopsis

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.

With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

About the Author

Dr. Jorg Knablein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).

AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest